checkAd

     193  0 Kommentare Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency - Seite 2

    Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group.  June 2021 Ascendis Pharma A/S.

    Investor contacts:   Media contact:
    Tim Lee   Ami Knoefler
    Ascendis Pharma   Ascendis Pharma
    (650) 374-6343   (650) 739-9952    
    tle@ascendispharma.com   ack@ascendispharma.com
         
    Patti Bank    
    Westwicke Partners        
    (415) 513-1284    
    patti.bank@westwicke.com    
    ir@ascendispharma.com    

     
    Seite 2 von 2



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Verfasst von globenewswire
    Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency - Seite 2 Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021COPENHAGEN, Denmark, June 11, 2021 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company …